Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3913]

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Adding daratumumab to VRd shows better efficacy outcomes compared to VRd alone...

Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands

Adding daratumumab to VRd shows better efficacy outcomes compared to VRd alone in multiple myeloma ( Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands )

Global Coalition for Radiotherapy - How to integrate radiotherapy in cancer...

Prof Richard Sullivan, Dr Lisa Stevens and Prof Pat Price

Global Coalition for Radiotherapy - How to integrate radiotherapy in cancer control plans ( Prof Richard Sullivan, Dr Lisa Stevens and Prof Pat Price )

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine...

Dr Lorraine Chantrill - University of Sydney, Sydney, Australia

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results ( Dr Lorraine Chantrill - University of Sydney, Sydney, Australia )

Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS...

Prof Hironaga Satake - Kochi Medical School, Kochi, Japan

Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC ( Prof Hironaga Satake - Kochi Medical School, Kochi, Japan )

Pembrolizumab a promising option for MIUC patients after radical surgery

Dr Andrea Apolo - National Cancer Institute, Bethesda, USA

Pembrolizumab a promising option for MIUC patients after radical surgery ( Dr Andrea Apolo - National Cancer Institute, Bethesda, USA )

ASCO GU 2024: Current best practice for mRCC

Prof Jens Bedke, Prof Thomas Powles, Prof Michael Staehler and Dr Wenxin Xu

ASCO GU 2024: Current best practice for mRCC ( Prof Jens Bedke, Prof Thomas Powles, Prof Michael Staehler and Dr Wenxin Xu )

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer

Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi...

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer ( Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi Kitamura )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Remote genetic testing has the potential to increase the uptake of testing in...

Dr Bruce Montgomery - University of Washington, Seattle, USA

Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems ( Dr Bruce Montgomery - University of Washington, Seattle, USA )

Stockholm3 offers a promising avenue for personalised risk-based prostate...

Dr Scott Eggener - The University of Chicago, Chicago, USA

Stockholm3 offers a promising avenue for personalised risk-based prostate cancer diagnosis ( Dr Scott Eggener - The University of Chicago, Chicago, USA )

Subcutaneous delivery of nivolumab is effective in treating metastatic ccRCC

Dr Saby George - Roswell Park Comprehensive Cancer Center, New York, USA

Subcutaneous delivery of nivolumab is effective in treating metastatic ccRCC ( Dr Saby George - Roswell Park Comprehensive Cancer Center, New York, USA )

More from ecancer